{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:12:58Z","timestamp":1761621178978,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ad.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T21:31:22Z","timestamp":1405978282000},"page":"809-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Queratosis act\u00ednica: un proceso ancestral, nuevos conceptos y enfoques terap\u00e9uticos"],"prefix":"10.1016","volume":"105","author":[{"given":"A.","family":"Alomar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 66","key":"10.1016\/j.ad.2014.06.002_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.0366-077X.2003.05625.x","article-title":"Pathology and pathobiology of the actinic (solar) keratosis","volume":"149","author":"Cockerell","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.2005.07121.x","article-title":"Solar (actinic) keratosis is squamous cell carcinoma","volume":"155","author":"Ackermann","year":"2006","journal-title":"Br J Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.ad.2014.06.002_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.07860.x","article-title":"Actinic keratosis is an early in situ squamous cell carcinoma: A proposal for reclassification","volume":"156","author":"Rowert-Huber","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0020","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ad.2013.11.013","article-title":"Adaptaci\u00f3n espa\u00f1ola de la gu\u00eda europea para la evaluaci\u00f3n y tratamiento de la queratosis act\u00ednica","volume":"105","author":"Ferr\u00e1ndiz","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2014.06.002_bib0030","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: A European Consensus","volume":"18","author":"Stockfleth","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"Supp 21","key":"10.1016\/j.ad.2014.06.002_bib0035","first-page":"1","article-title":"Actinic keratosis and field cancerisation","author":"Stockflet","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.12343","article-title":"Network meta-analysis of the outcome \u00abparticipant complete clearance\u00bb in non immunosuppressed participants of eight interventions for actinic keratosis: A follow-up on a Cochrane review","volume":"169","author":"Gupta","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0050","first-page":"536","article-title":"European guidelines for topical photodynamic therapy part 1: Treatment delivery and current indications\u2013actinic keratoses, Bowen's disease, basal cell carcinoma","volume":"27","author":"Morton","year":"2013","journal-title":"JEADV"},{"key":"10.1016\/j.ad.2014.06.002_bib0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0001-7310(08)74958-5","article-title":"Estudio retrospectivo, descriptivo y observacional del tratamiento de queratosis act\u00ednicas m\u00faltiples con metilaminolevulinato t\u00f3pico y luz roja: resultados en la pr\u00e1ctica cl\u00ednica y correlaci\u00f3n con la imagen de fluorescencia","volume":"99","author":"Fern\u00e1ndez Guarino","year":"2008","journal-title":"Actas Dermosifilogr"},{"key":"10.1016\/j.ad.2014.06.002_bib0060","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2147\/IJN.S45821","article-title":"In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles","volume":"8","author":"Shi","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ad.2014.06.002_bib0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","article-title":"Vehicle-controlled, randomized, double blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses of the head","volume":"157","author":"Alomar","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.ad.2014.06.002_bib0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2133.2007.08272.x","article-title":"Multicentre, open label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head","volume":"157","author":"Stockflet","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0075","first-page":"600","article-title":"Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety","volume":"11","author":"Martin","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2014.06.002_bib0085","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: Histological and clinical study results","volume":"165","author":"Stockfleth","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1684\/ejd.2012.1707","article-title":"Recurrence rates and patient assessed outcomes of 0,5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses","volume":"22","author":"Stockfleth","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0095","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0100","first-page":"165","article-title":"Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream","volume":"10","author":"Hanke","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ejd.2014.2265","article-title":"Reduction in lesions from Lmax: A new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%","volume":"24","author":"Stockflet","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0110","first-page":"163","article-title":"Reexamination of field-directed therapy for actinic keratosis","volume":"90","author":"Rosen","year":"2012","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2014.06.002_bib0115","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: A comprehensive strategy","volume":"11","author":"Stockfleth","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jaad.2012.09.051","article-title":"Current issues in the management of actinic keratosis","volume":"68","author":"Ceilley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaad.2012.10.001","article-title":"The importance of early diagnosis and treatment of actinic keratosis","volume":"68","author":"Rigel","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaad.2012.09.052","article-title":"Prevalence and awareness of actinic keratosis: Barriers and opportunities","volume":"68","author":"Rosen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaad.2012.09.053","article-title":"Pathobiology of actinic keratosis: Ultraviolet-dependent keratinocyte proliferation","volume":"68","author":"Berman","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2012.10.006","article-title":"Understanding actinic keratosis: Epidemiology, biology, and management of the disease","volume":"68","author":"Spencer","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2014.06.002_bib0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/09546634.2012.757285","article-title":"Patients\u2019 perceptions of topical treatments of actinic keratosis","volume":"25","author":"Esmann","year":"2014","journal-title":"J Dermatol Treat"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731014003159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731014003159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:02:26Z","timestamp":1757552546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731014003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0001731014003159"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2014.06.002","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Queratosis act\u00ednica: un proceso ancestral, nuevos conceptos y enfoques terap\u00e9uticos","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2014.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}